Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR6 | P51684 | 11/20 | 0.66 |
| ▸ | CXCR2 | P25025 | 10/20 | 0.52 |
| ▸ | CXCR1 | P25024 | 2/20 | 0.39 |
| ▸ | CXCR3 | P49682 | 1/20 | 0.39 |
| ▸ | CCR4 | P51679 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14450064 | 0.84 | CXCR2 (0.64) | CCR6CXCR2CXCR1 | |
| SCHEMBL13590558 | 0.80 | CXCR2 (0.49) | CCR6CXCR2CXCR1 | |
| SCHEMBL20732822 | 0.80 | CCR6 (1.00) | CCR6CXCR2CXCR1 | |
| SCHEMBL12087222 | 0.73 | CCR6 (0.85) | CCR6CXCR2CXCR1 | |
| SCHEMBL20721153 | 0.73 | CCR6 (0.68) | CCR6 | |
| SCHEMBL20721226 | 0.71 | CCR6 (0.68) | CCR6 | |
| SCHEMBL12086660 | 0.70 | CCR6 (0.80) | CCR6CXCR2CXCR1 | |
| SCHEMBL12087142 | 0.69 | CCR6 (0.57) | CCR6CXCR2CXCR1 | |
| SCHEMBL12087261 | 0.68 | CXCR2 (1.00) | CCR6CXCR2CXCR1 | |
| SCHEMBL12087229 | 0.68 | CXCR2 (1.00) | CCR6CXCR2CXCR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240400501-A1 | 3,4-DISUBSTITUTED 3-CYCLOBUTENE-1,2-DIONES AND USE THEREOF | ALLERGAN, INC. | 2024-12-05 | — | — | US | disclosed |
| US-20220402866-A1 | 3,4-DISUBSTITUTED 3-CYCLOBUTENE-1,2-DIONES AND USE THEREOF | ALLERGAN, INC. | 2022-12-22 | — | — | US | disclosed |
| US-11208377-B2 | 3,4-disubstituted 3-cyclobutene-1,2-diones and use thereof | ALLERGAN, INC. (US) | 2021-12-28 | — | — | US | disclosed |
| US-20190047947-A1 | 3,4-DISUBSTITUTED 3-CYCLOBUTENE-1,2-DIONES AND USE THEREOF | ALLERGAN, INC. | 2019-02-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240400501-A1 | 3,4-DISUBSTITUTED 3-CYCLOBUTENE-1,2-DIONES AND USE THEREOF | IL17A, TSLP, SSB | CCR6 197/4885CXCR2 303/4885CXCR1 156/4885 |
| US-11208377-B2 | 3,4-disubstituted 3-cyclobutene-1,2-diones and use thereof | IL17A, TSLP, SSB | CCR6 197/4885CXCR2 303/4885CXCR1 156/4885 |
| US-20220402866-A1 | 3,4-DISUBSTITUTED 3-CYCLOBUTENE-1,2-DIONES AND USE THEREOF | IL17A, TSLP, SSB | CCR6 197/4885CXCR2 303/4885CXCR1 156/4885 |
| US-20190047947-A1 | 3,4-DISUBSTITUTED 3-CYCLOBUTENE-1,2-DIONES AND USE THEREOF | IL17A, TSLP, SSB | CCR6 197/4885CXCR2 303/4885CXCR1 156/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.